Pancreatic Cancer | Specialty

Dr Spencer on the Rationale of Evaluating a Novel CAR T-Cell Product in Pancreatic Cancer

February 14th 2025

Kristen Spencer, DO, details the rationale of the phase 1/2 EVEREST-2 trial evaluating the novel CAR T product A2B694 in pancreatic cancer.

Dr Garrido-Laguna on the Safety and Efficacy of Daraxonrasib in KRAS-Mutated PDAC

February 6th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses updated safety and efficacy data with daraxonrasib in KRAS-mutated pancreatic ductal adenocarcinoma.

Dr Dotan on the Prognostic Value of QOL Assessments in Older Patients with Pancreatic Cancer

January 31st 2025

Efrat Dotan, MD, discusses gemcitabine plus nab-paclitaxel vs 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with metastatic pancreatic cancer.

OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer

January 28th 2025

Overall survival data were linked with baseline geriatric assessment and QOL scores in patients with metastatic pancreatic ductal adenocarcinoma.

Dr Oberstein on Data for Pamrevlumab Plus Nab-Paclitaxel/Gemcitabine in PDAC

January 28th 2025

Paul E. Oberstein, MD, discusses the efficacy and safety of pamrevlumab plus chemotherapy in first- and second-line PDAC.

Daraxonrasib Demonstrates Efficacy, Potential to Inhibit Major RAS(ON) Variants in RAS+ PDAC

January 28th 2025

Treatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

January 27th 2025

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

First-Line FOLFIRINOX Fails to Improve OS vs First-Line NALIRIFOX in Metastatic PDAC

January 25th 2025

The median OS with frontline FOLFIRINOX was numerically lower than that seen with frontline NALIRIFOX in patients with metastatic PDAC.

Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer

January 24th 2025

Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.

Dr Spira on RMC-9805 in KRAS G12D–Mutated Pancreatic Ductal Adenocarcinoma

January 24th 2025

Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC

January 24th 2025

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

Dr Goel on the Future of an Exosome-Based Liquid Biopsy Plus the Biomarker CA19-9 to Detect Early-Stage Pancreatic Cancer

January 24th 2025

Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.

IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer

January 20th 2025

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer

January 17th 2025

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

January 16th 2025

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

EMA Grants Orphan Medical Product Designation to Elraglusib in Advanced PDAC

January 11th 2025

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers

December 17th 2024

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

December 4th 2024

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

Tumor Treating Fields Plus Chemotherapy Improves OS in Unresectable Pancreatic Cancer

December 2nd 2024

First-line use of TTFields plus gemcitabine and nab-paclitaxel improved OS vs chemotherapy in unresectable, locally advanced pancreatic adenocarcinoma.

CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC

December 2nd 2024

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.